Original Article

Use of Cardiac Troponin Testing in the Outpatient Setting

Authors: Steven J. Ross, MD, Nikhil H. Shah, MD, Steve A. Noutong Njapo, MD, Daniel J. Cordiner, MD, David E. Winchester, MD, MS

Abstract

Objectives: Cardiac troponin (cTn) measurement is useful for diagnosing myocardial infarction (MI), particularly in the inpatient setting. A growing body of literature suggests that cTn may be useful for evaluating chronic conditions in the outpatient environment; however, little is known regarding cTn ordering patterns in this setting. We sought to investigate patterns of care and outcomes for patients evaluated with cTn in the outpatient setting. We hypothesized that a majority of outpatient cTn orders would be for the purpose of diagnosing possible MI.

Methods: We analyzed 228 patients who had outpatient orders for standard-sensitivity troponin T assays placed at our institution between January 1, 2013 and December 18, 2015. Data were divided into two cohorts based on the intended utility of cTn measurement: orders placed to evaluate for possible MI versus orders placed for some other purpose.

Results: Of the 228 patients, 161 were evaluated for possible MI and 67 for other reasons. Risk factors (hypertension P = 0.32, diabetes mellitus P = 0.41, coronary disease P = 0.38, heart failure P = 0.098, and chronic kidney disease P = 0.70) were similar between the cohorts. In the suspected MI cohort, an electrocardiogram was obtained in only 77% of patients, and only 13.1% were sent to the emergency department (ED) for further evaluation. Within the suspected MI cohort, 10.5% (n = 17) had elevated cTn and the majority of these patients (n = 10) were not sent to the ED.

Conclusions: The majority of outpatient cTn orders were intended to evaluate for MI, although electrocardiograms were frequently not ordered and few patients were sent for further ED evaluation. Providers should be encouraged to use cTn testing in a manner that minimizes the potential risk to patients with possible MI.
Posted in: Miscellaneous Cardiovascular Disease (Physical Examination Findings, Murmurs)2

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014; AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014130:e344-e426.
2. Hughes M, Lilleker JB, Herrick AL, et al. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis 2015;74:795-798.
3. Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116:2455-2461.
4. Poppi NT, Gowdak LH, Dourado LO, et al. A prospective study of patients with refractory angina: outcomes and the role of high-sensitivity troponin T. Clin Cardiol 2017;40:11-17.
5. Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med 2013;173:763-769.
6. Xanthakis V, Enserro DM, Larson MG, et al. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail 2016;4:808-815.
7. Okuyama R, Ishii J, Takahashi H, et al. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction. Heart Vessels 2017;32:880-892.
8. Roy AK, McCullagh BN, Segurado R, et al. Detection of high-sensitivity troponin in outpatients with stable pulmonary hypertension identifies a subgroup at higher risk of adverse outcomes. J Card Fail 2014;20:31-37.
9. Moreno V, Herná-Romero D, Vilchez JA, et al. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail 2010;16:950-956.
10. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
11. Farber AJ, Suarez K, Slicker K, et al. Frequency of troponin testing in inpatient versus outpatient settings. Am J Cardiol 2017;119:1153-1155.
12. Marshall GA, Wijeratne NG, Thomas D. Should general practitioners order troponin tests? Med J Aust 2014;201:155-157.
13. Shah ASV, Ferry AV, Mills NL. Cardiac biomarkers and the diagnosis of myocardial infarction in women. Curr Cardiol Rep 2017;19:40.
14. Tweet MS, Best P, Hayes SN. Unique presentations and etiologies of myocardial infarction in women. Curr Treat Options Cardiovasc Med 2017;19:66.
15. Pickering JW, Than MP, Cullen L, et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis. Ann Intern Med 2017;166:715-724.
16. Boeddinghaus J, Nestelberger T, Twerenbold R, et al. Direct comparison of 4 very early rule-out strategies for acute myocardial infarction using high-sensitivity cardiac troponin I. Circulation 2017;135:1597-1611.
17. Aroney CN, Cullen L. Appropriate use of serum troponin testing in general practice: a narrative review. Med J Aust 2016;205:91-94.
18. Gualandro DM, Puelacher C, Mueller C. High-sensitivity cardiac troponin in acute conditions. Curr Opin Crit Care 2014;20:472-477.
19. Nakamura Y, Yoshihisa A, Takiguchi M, et al. High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure. Circ J 2014;78:890-895.
20. Hassan HC, Howlin K, Jefferys A, et al. High-sensitivity troponin as a predictor of cardiac events and mortality in the stable dialysis population. Clin Chem 2014;60:389-398.
21. Rybicka J, Dobrowolski P, Lipczyń M, et al. High sensitivity troponin T in adult congenital heart disease. Int J Cardiol 2015;195:7-14.
22. Baba Y, Kubo T, Kitaoka H, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J 2012;53:287-292.
23. Blaes AH, Rehman A, Vock DM, et al. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag 2015;11:591-594.